|
View this as a webpage
Minnesota Department of Health
March 30, 2022
On March 29, 2022, the Food and Drug Administration (FDA) amended the emergency use authorization for the Pfizer-BioNTech and Moderna COVID-19 vaccines to include a second booster dose for people 50 years or older and people with certain immunocompromising conditions. The Centers for Disease Control and Prevention (CDC) updated their interim clinical considerations to state:
- People ages 18-49 years who are not moderately or severely immunocompromised and who received Janssen (Johnson & Johnson) COVID-19 vaccine as both their primary series dose and booster dose may receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose.
- People ages 50 years and older who are not moderately or severely immunocompromised may choose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster dose.
- People ages 12 years and older who are moderately or severely immunocompromised may choose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster dose.
FDA reports that emerging evidence suggests a second booster dose of an mRNA COVID-19 vaccine could improve protection against severe COVID-19, especially among the elderly and those with very weakened immune function and is not associated with new safety concerns. Refer to CDC’s interim clinical considerations and FDA and CDC media statements for further detail:
While this announcement focuses on a second booster, it is important that clinicians keep in mind that the primary series with a booster provides the greatest benefit and protection against hospitalization and death. Providers should focus on getting all people up to date with their COVID-19 vaccinations.
We are updating our MDH resources with these recent changes and they will be posted soon.
The Health Resources and Services Administration (HRSA) COVID-19 Uninsured Program (UIP) and COVID-19 Coverage Assistance Fund (CAF) will no longer accept vaccine administration claims after 10:59 p.m. on April 5 due to a lack of sufficient funds. Claims that have been submitted by these deadlines will be paid subject to eligibility and availability of funds. For further details refer to HRSA COVID-19 Uninsured Program Claims Submission Deadline FAQs or HRSA COVID-19 Coverage Assistance Fund Claims Submission Deadline FAQs.
We will provide updates if funding gets appropriated to continue reimbursement for these federal programs. Remember, the COVID-19 vaccination provider agreement states COVID-19 vaccines must be administered with no out-of-pocket cost to recipients, regardless of the recipient's ability to pay vaccine administration fees or coverage status.
For additional questions, contact the HRSA provider support line at 1-833-967-0770 or for TTY dial 1-888-970-2920, 7:00 a.m. to 7:00 p.m., Monday-Friday.
It is important that providers do not miss an opportunity to vaccinate. Well child visits can be a great opportunity to get children back on track with routine vaccinations and COVID-19 vaccinations. With ample COVID-19 vaccine supply and decreasing demand, it’s ok to open a new vial to vaccinate someone even if doses are wasted. Vaccine wastage is expected, and you can add up wasted doses and report once a week. Details on reporting wastage (nonviable vaccine) in MIIC can be found in Reporting Nonviable COVID-19 Vaccine to MIIC.
|
